Login / Signup

Toward the right treatment at the right time: Modeling the trajectory of cognitive decline to identify the earliest age of change in people with Alzheimer's disease.

R Asaad BakshAndré StrydomBen CarterIsabelle CarriereKaren Ritchie
Published in: Alzheimer's & dementia (Amsterdam, Netherlands) (2024)
Emax modeling could be used to design more efficient trials which has implications for randomized control trials targeting the earlier stages of AD.
Keyphrases
  • cognitive decline
  • mild cognitive impairment
  • open label
  • double blind
  • phase iii
  • clinical trial
  • placebo controlled
  • cancer therapy
  • randomized controlled trial
  • combination therapy
  • drug delivery